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CD9 is a transmembrane protein that has been implicated in cell adhesion, motility and proliferation, and numerous studies have
demonstrated the prognostic value of its expression in different solid tumours. The purpose of this study is to determine the
predictive value of CD9 in squamous cell carcinoma (SCC) of the head and neck. A total of 153 cases were examined for CD9
expression using immunohistochemistry applied on formalin-fixed, paraffin-embedded tissue. Cases were stratified in two categories
depending on CD9 expression, as positive (X50% positive cells) or reduced (o50%). In all, 108 cases were positive for CD9 (85
cases with membranous, and 23 with both membranous and cytoplasmic staining) and 45 reduced expression. Reduced CD9
expression was significantly associated with high grade (P¼0.0007) and lower disease-free survival (DFS) (P¼0.017). The latter
retained its significance in the multivariate analysis. When the 23 cases with both membranous and cytoplasmic patterns were studied
as a separate subgroup, there were significant associations between CD9 expression and tumour grade (P¼0.025) (95% CI 11–68),
tumour stage (P¼0.08) (95% CI 3.5–86) and the occurrence of any failure (P¼0.083) (95% CI  1.7–57). Immunohistochemical
CD9 expression proved to be an independent prognostic factor in SCC of the head and neck, and it may detect patients at a high risk
of recurrence. In addition, the cytoplasmic pattern seems to have an even more significant value. However, this finding is limited to
the small number of cases with this pattern.
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Despite the important advances made in the management of
squamous cell carcinoma (SCC) of the head and neck, patients
still have poor prognosis with a 5-year disease-free survival (DFS)
of about 50% (Landis et al, 1999). The prognostic factors
are mostly confined to the histopathologic and clinical
parameters such as grade, stage, pattern of invasion, location
and lymph node metastasis (Crissman et al, 1984; Pera et al,
1986; Wiernik et al, 1991; DeStefani et al, 1997). Recently,
numerous molecular markers such as cell cycle regulators,
cell adhesion proteins, oncogenes and tumour-suppressor genes
have been investigated in SCC of the head and neck, and some
of these markers have shown promising results for future
use (Schoelch et al, 1999; Grabenbauer et al, 2000; Pukkila
et al, 2001; Khademi et al, 2002; Khan et al, 2002; Liu et al,
2003).
Disruption of cell adhesion and alteration of cell motility play an
important role in cancer cell invasion and metastasis. Previously,
CD9 was reported to be of prognostic significance in adenocarci-
noma of the lung, colon, breast, pancreas and SCC of the
oesophagus and the oral cavity. Motility-related protein
(MRP-1)/CD9 is a member of the transmembrane 4 superfamily
(TM4SF) which is involved in cell growth, adhesion and
motility. Of the 20 known members, five – MRP1/CD9, ME491/
CD63, KAI1/CD82, CD151, CD81 – may be implicated in
cell migration, proliferation and tumour cell metastasis
(Miyake et al, 1991; Ikeyama et al, 1993). The motility-related
protein/CD9 is so far the best characterised of the TM4SF
members. It is located on chromosome 12 (12p13) and is
widely distributed among all cell types. CD9 is capable of
interacting with other transmembrane proteins such as
integrins and other tetraspanins to form a complex, which
facilitates cell adhesion, motility and signalling (Hemler
et al, 1996). Thus, CD9 appears to have an important role in
inhibiting cell motility in numerous neoplastic cell lines (Miyake
et al, 1991).
Studies evaluating the expression of this CD9 protein in SCC of
the head and neck are nonexistent, save only for one study, and it
was limited to the SCC of the oral cavity (Kusukawa et al, 2001).
Thus, the aim of this study is to assess the utility of the CD9
protein expression in predicting DFS of patients with SCC arising
in the head and neck after treatment with radiotherapy (RT) with
or without chemotherapy.
Received 26 June 2003; revised 9 October 2003; accepted 5 November
2003
*Correspondence: P Mhawech;
E-mail: Paulette.Mhawech-Fauceglia@hcuge.ch
British Journal of Cancer (2004) 90, 471–475
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yMATERIALS AND METHODS
Patients population
A retrospective study covering 7 years (1992–1999) was con-
ducted. The criteria for inclusion were patients with no prior
treatment, histologic diagnosis performed in our department and
adequate material for analysis. Tumours with a nasopharyngeal
origin were excluded from the study. From 201 registered patients,
153 met our criteria for inclusion. The patient and tumour
characteristics are summarised in Table 1. After the initial
diagnosis, patients were treated with radical RT with or without
chemotherapy. All patients were regularly followed up by the
otolaryngologist, and the radio-oncologist. Therapy modality and
follow-up data were retrieved from the registry at the Division of
Radiation Oncology. The median follow-up for the surviving
patients was 65 months (range 14–123).
Treatment
All patients received the same accelerated RT schedule using
concomitant boost technique. The latter has been described
previously in detail (Allal et al, 1999). The planned total dose
was 69.9Gy, delivered in 41 fractions over a period of 38 days. The
basic course was given to a total dose of 50.4Gy over 5.5 weeks.
The boost to the initial sites of macroscopic tumour involvement
consisted of 19.5Gy, and was given as a second daily fraction,
starting the last day of the second week of the basic treatment.
According to our institutional policy, 20 patients (13%) underwent
a planned neck dissection prior to RT, either radical or modified
radical, while one patient had simple excisions of lymph node
metastases. Otherwise, surgery was reserved for salvage of
locoregional failures.
Chemotherapy was given to 38 patients (25%), usually for
patients presenting with T3–4 or N2–3 tumours, if their medical
condition was judged fit enough to tolerate multimodality
treatment. Except for two patients who received induction
chemotherapy, all patients received one or more cycles of cisplatin
and 5-FU-based chemotherapy, concomitantly with RT.
Immunohistochemistry
The tissue analysed consisted of initial (pretreatment) biopsies.
The original diagnosis was reviewed by two pathologists (PM, ET)
and the histologic grade was assessed using the WHO system.
Immunohistochemistry (IHC) was performed on paraffin-em-
bedded tissues. Tissue sections were deparaffinised with xylene
and washed with ethanol. For immunostaining enhancement,
pretreatment by microwave oven in 0.01 M citrate buffer (pH 6.0) at
981C for 30min was done. Sections were incubated with a
monoclonal anti-CD9 antibody (Novacastra, Newcastle, UK),
diluted at 1:20. Endogenous peroxidase was blocked with 0.3%
hydrogen peroxidase for 5min. Sections were then incubated with
mouse Envision horseradish peroxidase (HRP) for 30min. IHC
was performed using the automated stainer Dako ‘Autostainer’
(Dako, Copenhagen, Denmark). These incubations were performed
at room temperature, and sections were washed by Tris buffer
saline between incubations. Diaminobenzidine complex was used
as chromogen. Tissue sections from cases of fibroadenoma were
taken as positive controls. Staining of normal squamous epithe-
lium with anti-CD9 showed strong membranous positivity
(Figure 1). In negative controls, a normal goat serum was used
in place of the primary antibody, resulting in a lack of detectable
staining. Evaluation of the IHC was done twice by one pathologist
(PM) at 2 weeks interval. All the tissue on the slide was scanned for
CD9 expression, and the average was calculated for the entire slide.
Samples for CD9 expression were stratified into two categories,
depending on the percentage of CD9-positive cells of any pattern
(cytoplsamic/membranous). Cases showing X50% CD9-positive
tumour cells were classified as ‘positive’, while cases with o50%
stained tumour cells were considered as ‘reduced’ cases.
Statistical analysis
The Mann–Whitney and Kruskal–Wallis tests were used to
compare the CD9 median values of the different subgroups. The
actuarial overall and DFS rates were calculated using the Kaplan–
Meier method. For comparison between curves, the log-rank test
was used. Multivariate analyses based on Cox proportional hazards
standard model were used to identify the most significant factors
related to outcomes. P-values of 0.05 or less were considered
significant. All analysis was performed with the StatView V 5.0.1
software.
RESULTS
Overall results
At last follow-up, 58 patients were alive, and 95 had died. In all, 56
patients presented with one or more events. A total of 33 patients
presented with persistent or recurrent local disease, 15 with
Figure 1 Tissue from normal laryngeal mucosae showed positive staining
for CD9 using IHC in the squamous epithelium, while the connective tissue
is negative. The squamous epithelial cells are positive with membranous
pattern (inset).
Table 1 Patients and tumours characteristics
Median age (years) (range) 59 (35–90)
Sex M:F 122/31
Tumour sublocation
Oral cavity 8
Oropharynx 93
Hypopharynx 25
Larynx 27
TN classification and stages (UICC 1997)
T1–2 64
T3–4 89
NO 72
N+ 81
Stage I–II 35
Stage III–IV 118
Histology grading
Well differentiated (G1) 64
Moderately differentiated (G2) 66
Poorly differentiated (G3) 23
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(16 distant only). At 5 years, actuarial DFS was 58% (95% CI 0.49–
0.67) and overall survival was 38% (95% CI 0.30–0.46).
CD9 expression and clinicopathologic associations
On CD9 evaluation, 108 cases were CD9 positive with any staining
pattern (cytoplasmic/membranous) and 45 showed reduced
expression. Of the 108 positive cases, 85 had membranous staining
and 23 had both membranous and cytoplasmic staining (Figures 2,
3). CD9 are expressed in 100, 70 and 10% of G1, G2 and G3 cases,
respectively. When the CD9 expression was compared with various
clinical features, there was no significant association between the
CD9 expression and T stage (P¼0.41), lymph node status
(P¼0.53), UICC stage grouping system (0.77) or tumour
sublocation (P¼0.3). However, there was a highly significant
association between CD9 expression and tumour grade
(P¼0.0007).
Univariate and multivariate analyses
In the univariate analysis, besides advanced T (P¼0.013) and N
categories (P¼0.002) and UICC stage (P¼0.002), the reduced
expression of CD9 was significantly associated with lower 5-year
DFS (43% vs 64%, P¼0.018) (Figure 4). Histology grading (G1 vs
G2–3) (Figure 5) and treatment category (with or without
chemotherapy) did not correlate significantly with DFS.
Factors significantly influencing DFS in univariate analysis were
included in the Cox model (except linked variables). In such a
model, T-category (P¼0.024), N-category (P¼0.012) and CD9
expression (P¼0.017) retained their significance for DFS, and can
consequently be considered as independent factors in predicting
tumour failure. The relative risks associated with these factors are
listed in Table 2. In a similar model, when substituting CD9
expression by tumour grading (G1 vs G2–3), the impact of the
latter on DFS remained nonsignificant (P¼0.3).
Subgroup analysis
By contrast to tumours expressing only membranous CD9, the 23
tumours with both membranous and cytoplasmic staining showed
Figure 2 An example of positive staining for CD9, where 90% of
tumour cells showed a strong reactivity with a membranous pattern.
Figure 3 An example of the combined pattern where 490% of tumour
cells showed CD9 expression in both membranous and cytoplasmic
patterns.
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Figure 5 Actuarial DFS according to the histological grading (G1 vs G2–
3) (log-rank test 0.16).
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Figure 4 Actuarial DFS after therapy according to CD9 expression (all
staining patterns (log-rank test of 0.018)).
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(95% CI 3.5–86) and disease failure (P¼0.083) (95% CI  1.7–57),
while the association with tumour grade (G1 vs G2–3) was less
strong (P¼0.025 vs 0.0006) (95% CIs 11–68 vs 10–37). Thus, in
this subgroup (membranous and cytoplasmic staining), the mean
tumour CD9 values in patients with and without any oncological
event were 37 and 65%, respectively (P¼0.08). The impact of CD9
expression on the 5-year actuarial DFS was more significant in the
subgroup with both membranous and cytoplasmic pattern
compared to the subgroup with membranous pattern only
(P¼0.009 vs 0.04).
DISCUSSION
The present study of 153 patients with a long-term follow-up is the
first to investigate the value of CD9 protein in SCC of the head and
neck. Among all parameters analysed, such as tumour grade,
location, age, lymph node status, UICC stage classification, tumour
grade was the only parameter to show a significant association
with CD9 expression: low grade tumours appeared to express the
CD9 protein more frequently. On the other hand, the present study
indicates that reduced CD9 expression by tumour cells seems to
predict disease progression after RT with or without chemother-
apy. The link between reduced CD9 expression and tumour failure
was independent of tumour T and N –categories, as found in the
multivariate analysis. If CD9 is to be considered for clinical used in
the future, that might add an additional 18 pound sterling to the
patient’s bill (which is an almost insignificant cost).
The expression of CD9 using the IHC technique has been
identified in numerous solid tumours. By evaluating CD9
expression in oesophageal SCC, Uchida et al found that the 5-
year survival rate of patients with reduced CD9 is worser than
those with positive CD9 expression (Uchida et al, 1999). Miyake
et al (1996) found that reduced CD9 expression is strongly
associated with a high frequency of metastatic lymph node in
breast cancer patients, and might be used to identify patients at
high risk for disease recurrence. Huang et al (1998) also showed
the prognostic value of CD9 in patients with breast cancer. In their
study, CD9-positive expression predicted a better rate of DFS.
Higashiyama et al (1997) showed an inverse relation between CD9
expression and DFS in patients with lung adenocarcinoma. In all
these studies, CD9 expression was seen as a membranous pattern.
However, there are two investigations in the literature describing
both the cytoplasmic and membranous patterns, as noted in our
study in addition to the usual membranous staining. The first was
by Kawashima et al (2002) and the second was by Houle et al
(2002)). In the former, CD9 expression was evaluated in different
types of brain tumours, and they concluded that CD9 expression in
astrocytic tumours correlated with their malignancy and thus CD9
protein may have a different role in brain tumours than solid
tumours elsewhere. However, the cytoplasmic staining was not
commented on. The latter evaluated CD9 expression in ovarian
carcinoma. Loss of CD9 was found to be associated with tumour
grade and, in particular, cytoplasmic CD9 expression with higher
tumour grade. However, the study consisted of a small number of
cases (38 cases), and the cytoplasmic staining was seen in a very
few cases and very focally. Thus, the authors themselves did not
reach any conclusion on the significance of their finding due to the
size of the sample analysed. In addition, the cutoff value for
positivity was not mentioned. In our study, we find that the impact
of CD9 expression on DFS was more significant in the subgroup
with both membranous and cytoplasmic patterns, compared to the
subgroup with membranous pattern only. In addition, besides its
association to tumour grade, there was an association with another
prognostic parameter, tumour stage. However, due to the small
sample size, we are not able to assess the true significance of this
finding and we cannot really draw an accurate conclusion. Studies
with larger samples are needed to clarify the true meaning of this
finding. The only study with results directly comparable to ours is
that by Kusukawa et al, who found a strong association between
loss of CD9 expression and high incidence of lymph node
metastasis and poor prognosis of patients with SCC of the oral
cavity. However, in this study, the cutoff value for positive tumour
was not clearly stated, and multivariate study using the Cox
regression analysis was not done.
The ability of neoplastic cells to invade the surrounding tissue
and metastasis to distant organs comes from the disruption of cell
adhesion and alteration of cell motility. CD9, which plays an
important role in cell growth, cell adhesion and motility, seems to
be an ideal candidate. In this study, we showed that CD9
expression in SCC of the head and neck may be an independent
factor in predicting DFS, and consequently it may have a potential
use in identifying patients with higher risk of recurrence after
therapy.
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